Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement

Author(s): Darby J.E. Lowe, Daniel J. Müller*, Tony P. George

Journal Name: Current Topics in Medicinal Chemistry

Volume 20 , Issue 15 , 2020

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Ketamine has been shown to be efficacious for the treatment of depression, specifically among individuals who do not respond to first-line treatments. There is still, however, a lack of clarity surrounding the clinical features and response periods across samples that respond to ketamine. This paper systematically reviews published randomized controlled trials that investigate ketamine as an antidepressant intervention in both unipolar and bipolar depression to determine the specific clinical features of the samples across different efficacy periods. Moreover, similarities and differences in clinical characteristics associated with acute versus longer-term drug response are discussed. Similarities across all samples suggest that the population that responds to ketamine’s antidepressant effect has experienced chronic, long-term depression, approaching ketamine treatment as a “last resort”. Moreover, differences between these groups suggest future research to investigate the potential of stronger efficacy towards depression in the context of bipolar disorder compared to major depression, and in participants who undergo antidepressant washout before ketamine administration. From these findings, suggestions for the future direction of ketamine research for depression are formed.

Keywords: Ketamine, Depression, Bipolar disorder, Clinical characteristics, Pharmacogenetics, Glutamatergic dysfunction.

[1]
Organization, W.H. Depression., Available at:. https://www.who. int/news-room/fact-sheets/detail/depression (Accessed on March 15).
[2]
Lloyd, L.C.; Giaroli, G.; Taylor, D.; Tracy, D.K. Bipolar depression: clinically missed, pharmacologically mismanaged. Ther. Adv. Psychopharmacol., 2011, 1(5), 153-162.
[http://dx.doi.org/10.1177/2045125311420752] [PMID: 23983940]
[3]
Rush, A.J.; Trivedi, M.H.; Wisniewski, S.R.; Nierenberg, A.A.; Stewart, J.W.; Warden, D.; Niederehe, G.; Thase, M.E.; Lavori, P.W.; Lebowitz, B.D.; McGrath, P.J.; Rosenbaum, J.F.; Sackeim, H.A.; Kupfer, D.J.; Luther, J.; Fava, M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry, 2006, 163(11), 1905-1917.
[http://dx.doi.org/10.1176/ajp.2006.163.11.1905] [PMID: 17074942]
[4]
Fava, M.; Rush, A.J.; Alpert, J.E.; Balasubramani, G.K.; Wisniewski, S.R.; Carmin, C.N.; Biggs, M.M.; Zisook, S.; Leuchter, A.; Howland, R.; Warden, D.; Trivedi, M.H. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am. J. Psychiatry, 2008, 165(3), 342-351.
[http://dx.doi.org/10.1176/appi.ajp.2007.06111868] [PMID: 18172020]
[5]
Jick, H.; Kaye, J.A.; Jick, S.S. Antidepressants and the risk of suicidal behaviors. JAMA, 2004, 292(3), 338-343.
[http://dx.doi.org/10.1001/jama.292.3.338] [PMID: 15265848]
[6]
Moussavi, S.; Chatterji, S.; Verdes, E.; Tandon, A.; Patel, V.; Ustun, B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet, 2007, 370(9590), 851-858.
[http://dx.doi.org/10.1016/S0140-6736(07)61415-9] [PMID: 17826170]
[7]
Skolnick, P.; Popik, P.; Trullas, R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol. Sci., 2009, 30(11), 563-569.
[http://dx.doi.org/10.1016/j.tips.2009.09.002] [PMID: 19837463]
[8]
Murrough, J.W.; Abdallah, C.G.; Mathew, S.J. Targeting glutamate signalling in depression: progress and prospects. Nat. Rev. Drug Discov., 2017, 16(7), 472-486.
[http://dx.doi.org/10.1038/nrd.2017.16] [PMID: 28303025]
[9]
Li, L.; Vlisides, P.E. Ketamine: 50 years of modulating the mind. Front. Hum. Neurosci., 2016, 10, 612.
[http://dx.doi.org/10.3389/fnhum.2016.00612] [PMID: 27965560]
[10]
Lapidus, K.A.; Soleimani, L.; Murrough, J.W. Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr. Dis. Treat., 2013, 9, 1101-1112.
[PMID: 23976856]
[11]
Krystal, J.H.; Sanacora, G.; Duman, R.S. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol. Psychiatry, 2013, 73(12), 1133-1141.
[http://dx.doi.org/10.1016/j.biopsych.2013.03.026] [PMID: 23726151]
[12]
Paul, I.A.; Skolnick, P. Glutamate and depression: clinical and preclinical studies. Ann. N. Y. Acad. Sci., 2003, 1003(1), 250-272.
[http://dx.doi.org/10.1196/annals.1300.016] [PMID: 14684451]
[13]
Berman, R.M.; Cappiello, A.; Anand, A.; Oren, D.A.; Heninger, G.R.; Charney, D.S.; Krystal, J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry, 2000, 47(4), 351-354.
[http://dx.doi.org/10.1016/S0006-3223(99)00230-9] [PMID: 10686270]
[14]
Li, C.T.; Chen, M.H.; Lin, W.C.; Hong, C.J.; Yang, B.H.; Liu, R.S.; Tu, P.C.; Su, T.P. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study. Hum. Brain Mapp., 2016, 37(3), 1080-1090.
[http://dx.doi.org/10.1002/hbm.23085] [PMID: 26821769]
[15]
Jafarinia, M.; Afarideh, M.; Tafakhori, A.; Arbabi, M.; Ghajar, A.; Noorbala, A.A.; Saravi, M.A.; Agah, E.; Akhondzadeh, S. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. J. Affect. Disord., 2016, 204, 1-8.
[http://dx.doi.org/10.1016/j.jad.2016.05.076] [PMID: 27317968]
[16]
Murrough, J.W.; Burdick, K.E.; Levitch, C.F.; Perez, A.M.; Brallier, J.W.; Chang, L.C.; Foulkes, A.; Charney, D.S.; Mathew, S.J.; Iosifescu, D.V. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology, 2015, 40(5), 1084-1090.
[http://dx.doi.org/10.1038/npp.2014.298] [PMID: 25374095]
[17]
Kim, J.; Farchione, T.; Potter, A.; Chen, Q.; Temple, R. Esketamine for treatment-resistant depression-first FDA-approved antidep-ressant in a new class. N. Engl. J. Med., 2019, 381(1), 1-4.
[18]
Walter, M.; Li, S.; Demenescu, L.R. Multistage drug effects of ketamine in the treatment of major depression. Eur. Arch. Psychiatry Clin. Neurosci., 2014, 264(1)(Suppl. 1), S55-S65.
[http://dx.doi.org/10.1007/s00406-014-0535-3] [PMID: 25217177]
[19]
Miller, A.H. Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression. Neuropsychopharmacology, 2013, 38(9), 1607-1608.
[http://dx.doi.org/10.1038/npp.2013.140] [PMID: 23857540]
[20]
Guo, W.; Machado-Vieira, R.; Mathew, S.; Murrough, J.W.; Charney, D.S.; Grunebaum, M.; Oquendo, M.A.; Kadriu, B.; Akula, N.; Henter, I.; Yuan, P.; Merikangas, K.; Drevets, W.; Furey, M.; Mann, J.J.; McMahon, F.J.; Zarate, C.A., Jr; Shugart, Y.Y. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Transl. Psychiatry, 2018, 8(1), 280.
[http://dx.doi.org/10.1038/s41398-018-0311-7] [PMID: 30552317]
[21]
Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med., 2009, 151(4), 264-269. , W64
[http://dx.doi.org/10.7326/0003-4819-151-4-200908180-00135] [PMID: 19622511]
[22]
Williams, J.B. A structured interview guide for the Hamilton Depression Rating Scale. Arch. Gen. Psychiatry, 1988, 45(8), 742-747.
[http://dx.doi.org/10.1001/archpsyc.1988.01800320058007] [PMID: 3395203]
[23]
Müller, M.J.; Himmerich, H.; Kienzle, B.; Szegedi, A. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J. Affect. Disord., 2003, 77(3), 255-260.
[http://dx.doi.org/10.1016/S0165-0327(02)00120-9] [PMID: 14612225]
[24]
Rush, A.J.; Giles, D.E.; Schlesser, M.A.; Fulton, C.L.; Weissenburger, J.; Burns, C. The inventory for depressive symptomatology (IDS): preliminary findings. Psychiatry Res., 1986, 18(1), 65-87.
[http://dx.doi.org/10.1016/0165-1781(86)90060-0] [PMID: 3737788]
[25]
Lally, N.; Nugent, A.C.; Luckenbaugh, D.A.; Ameli, R.; Roiser, J.P.; Zarate, C.A. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl. Psychiatry, 2014, 4(10), e469
[http://dx.doi.org/10.1038/tp.2014.105] [PMID: 25313512]
[26]
Price, R.B.; Iosifescu, D.V.; Murrough, J.W.; Chang, L.C.; Al Jurdi, R.K.; Iqbal, S.Z.; Soleimani, L.; Charney, D.S.; Foulkes, A.L.; Mathew, S.J. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress. Anxiety, 2014, 31(4), 335-343.
[http://dx.doi.org/10.1002/da.22253] [PMID: 24668760]
[27]
Singh, J.B.; Fedgchin, M.; Daly, E.; Xi, L.; Melman, C.; De Bruecker, G.; Tadic, A.; Sienaert, P.; Wiegand, F.; Manji, H.; Drevets, W.C.; Van Nueten, L. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol. Psychiatry, 2016, 80(6), 424-431.
[http://dx.doi.org/10.1016/j.biopsych.2015.10.018] [PMID: 26707087]
[28]
George, D.; Gálvez, V.; Martin, D.; Kumar, D.; Leyden, J.; Hadzi-Pavlovic, D.; Harper, S.; Brodaty, H.; Glue, P.; Taylor, R.; Mitchell, P.B.; Loo, C.K. Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. Am. J. Geriatr. Psychiatry, 2017, 25(11), 1199-1209.
[http://dx.doi.org/10.1016/j.jagp.2017.06.007] [PMID: 28739263]
[29]
Loo, C.K.; Gálvez, V.; O’Keefe, E.; Mitchell, P.B.; Hadzi-Pavlovic, D.; Leyden, J.; Harper, S.; Somogyi, A.A.; Lai, R.; Weickert, C.S.; Glue, P. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr. Scand., 2016, 134(1), 48-56.
[http://dx.doi.org/10.1111/acps.12572] [PMID: 27028832]
[30]
Lai, R.; Katalinic, N.; Glue, P.; Somogyi, A.A.; Mitchell, P.B.; Leyden, J.; Harper, S.; Loo, C.K. Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. WFSBP, 2014, 15(7), 579-584.
[31]
Lapidus, K.A.; Levitch, C.F.; Perez, A.M.; Brallier, J.W.; Parides, M.K.; Soleimani, L.; Feder, A.; Iosifescu, D.V.; Charney, D.S.; Murrough, J.W. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol. Psychiatry, 2014, 76(12), 970-976.
[http://dx.doi.org/10.1016/j.biopsych.2014.03.026] [PMID: 24821196]
[32]
Downey, D.; Dutta, A.; McKie, S.; Dawson, G.R.; Dourish, C.T.; Craig, K.; Smith, M.A.; McCarthy, D.J.; Harmer, C.J.; Goodwin, G.M.; Williams, S.; Deakin, J.F. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate. Eur. Neuropsychopharmacol., 2016, 26(6), 994-1003.
[http://dx.doi.org/10.1016/j.euroneuro.2016.03.006] [PMID: 27133029]
[33]
Fan, W.; Yang, H.; Sun, Y.; Zhang, J.; Li, G.; Zheng, Y.; Liu, Y. Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. Oncotarget, 2017, 8(2), 2356-2360.
[http://dx.doi.org/10.18632/oncotarget.13743] [PMID: 27926528]
[34]
Murrough, J.W.; Soleimani, L.; DeWilde, K.E.; Collins, K.A.; Lapidus, K.A.; Iacoviello, B.M.; Lener, M.; Kautz, M.; Kim, J.; Stern, J.B.; Price, R.B.; Perez, A.M.; Brallier, J.W.; Rodriguez, G.J.; Goodman, W.K.; Iosifescu, D.V.; Charney, D.S. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol. Med., 2015, 45(16), 3571-3580.
[http://dx.doi.org/10.1017/S0033291715001506] [PMID: 26266877]
[35]
Chen, M-H.; Li, C-T.; Lin, W-C.; Hong, C-J.; Tu, P-C.; Bai, Y-M.; Cheng, C-M.; Su, T-P. Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study. J. Affect. Disord., 2018, 225, 709-714.
[http://dx.doi.org/10.1016/j.jad.2017.09.008] [PMID: 28922734]
[36]
Salvadore, G.; Cornwell, B.R.; Colon-Rosario, V.; Coppola, R.; Grillon, C.; Zarate, C.A., Jr; Manji, H.K. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol. Psychiatry, 2009, 65(4), 289-295.
[http://dx.doi.org/10.1016/j.biopsych.2008.08.014] [PMID: 18822408]
[37]
Murrough, J.W.; Iosifescu, D.V.; Chang, L.C.; Al Jurdi, R.K.; Green, C.E.; Perez, A.M.; Iqbal, S.; Pillemer, S.; Foulkes, A.; Shah, A.; Charney, D.S.; Mathew, S.J. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am. J. Psychiatry, 2013, 170(10), 1134-1142.
[http://dx.doi.org/10.1176/appi.ajp.2013.13030392] [PMID: 23982301]
[38]
Ghasemi, M.; Kazemi, M.H.; Yoosefi, A.; Ghasemi, A.; Paragomi, P.; Amini, H.; Afzali, M.H. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res., 2014, 215(2), 355-361.
[http://dx.doi.org/10.1016/j.psychres.2013.12.008] [PMID: 24374115]
[39]
Zarate, C.A., Jr; Singh, J.B.; Carlson, P.J.; Brutsche, N.E.; Ameli, R.; Luckenbaugh, D.A.; Charney, D.S.; Manji, H.K. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry, 2006, 63(8), 856-864.
[http://dx.doi.org/10.1001/archpsyc.63.8.856] [PMID: 16894061]
[40]
Valentine, G.W.; Mason, G.F.; Gomez, R.; Fasula, M.; Watzl, J.; Pittman, B.; Krystal, J.H.; Sanacora, G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res., 2011, 191(2), 122-127.
[http://dx.doi.org/10.1016/j.pscychresns.2010.10.009] [PMID: 21232924]
[41]
Zarate, C.A., Jr; Brutsche, N.E.; Ibrahim, L.; Franco-Chaves, J.; Diazgranados, N.; Cravchik, A.; Selter, J.; Marquardt, C.A.; Liberty, V.; Luckenbaugh, D.A. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry, 2012, 71(11), 939-946.
[http://dx.doi.org/10.1016/j.biopsych.2011.12.010] [PMID: 22297150]
[42]
Sos, P.; Klirova, M.; Novak, T.; Kohutova, B.; Horacek, J.; Palenicek, T. Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinol. Lett., 2013, 34(4), 287-293.
[PMID: 23803871]
[43]
Reed, J.L.; Nugent, A.C.; Furey, M.L.; Szczepanik, J.E.; Evans, J.W.; Zarate, C.A., Jr Ketamine normalizes brain activity during emotionally valenced attentional processing in depression. Neuroimage Clin., 2018, 20, 92-101.
[http://dx.doi.org/10.1016/j.nicl.2018.07.006] [PMID: 30094160]
[44]
Diazgranados, N.; Ibrahim, L.; Brutsche, N.E.; Newberg, A.; Kronstein, P.; Khalife, S.; Kammerer, W.A.; Quezado, Z.; Luckenbaugh, D.A.; Salvadore, G.; Machado-Vieira, R.; Manji, H.K.; Zarate, C.A., Jr A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry, 2010, 67(8), 793-802.
[http://dx.doi.org/10.1001/archgenpsychiatry.2010.90] [PMID: 20679587]
[45]
Ibrahim, L.; Diazgranados, N.; Franco-Chaves, J.; Brutsche, N.; Henter, I.D.; Kronstein, P.; Moaddel, R.; Wainer, I.; Luckenbaugh, D.A.; Manji, H.K.; Zarate, C.A., Jr Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology, 2012, 37(6), 1526-1533.
[http://dx.doi.org/10.1038/npp.2011.338] [PMID: 22298121]
[46]
Singh, J.B.; Fedgchin, M.; Daly, E.J.; De Boer, P.; Cooper, K.; Lim, P.; Pinter, C.; Murrough, J.W.; Sanacora, G.; Shelton, R.C.; Kurian, B.; Winokur, A.; Fava, M.; Manji, H.; Drevets, W.C.; Van Nueten, L. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am. J. Psychiatry, 2016, 173(8), 816-826.
[http://dx.doi.org/10.1176/appi.ajp.2016.16010037] [PMID: 27056608]
[47]
Grunebaum, M.F.; Ellis, S.P.; Keilp, J.G.; Moitra, V.K.; Cooper, T.B.; Marver, J.E.; Burke, A.K.; Milak, M.S.; Sublette, M.E.; Oquendo, M.A.; Mann, J.J. Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. Bipolar Disord., 2017, 19(3), 176-183.
[http://dx.doi.org/10.1111/bdi.12487] [PMID: 28452409]
[48]
Niciu, M.J.; Luckenbaugh, D.A.; Ionescu, D.F.; Guevara, S.; Machado-Vieira, R.; Richards, E.M.; Brutsche, N.E.; Nolan, N.M.; Zarate, C.A., Jr Clinical predictors of ketamine response in treatment-resistant major depression. J. Clin. Psychiatry, 2014, 75(5), e417-e423.
[http://dx.doi.org/10.4088/JCP.13m08698] [PMID: 24922494]
[49]
Kaufman, J.; Charney, D. Comorbidity of mood and anxiety disorders. Depress. Anxiety, 2000, 12(S1)(Suppl. 1), 69-76.
[http://dx.doi.org/10.1002/1520-6394(2000)12:1+<69:AID-DA9>3.0.CO;2-K] [PMID: 11098417]
[50]
Fava, M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry, 2003, 53(8), 649-659.
[http://dx.doi.org/10.1016/S0006-3223(03)00231-2] [PMID: 12706951]
[51]
Guo, W.B.; Liu, F.; Chen, J.D.; Xu, X.J.; Wu, R.R.; Ma, C.Q.; Gao, K.; Tan, C.L.; Sun, X.L.; Xiao, C.Q.; Chen, H.F.; Zhao, J.P. Altered white matter integrity of forebrain in treatment-resistant depression: a diffusion tensor imaging study with tract-based spatial statistics. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012, 38(2), 201-206.
[http://dx.doi.org/10.1016/j.pnpbp.2012.03.012] [PMID: 22504778]
[52]
Li, C-T.; Su, T-P.; Wang, S-J.; Tu, P-C.; Hsieh, J-C. Prefrontal glucose metabolism in medication-resistant major depression. Br. J. Psychiatry, 2015, 206(4), 316-323.
[http://dx.doi.org/10.1192/bjp.bp.113.140434] [PMID: 25657357]
[53]
Duman, R.S. Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depress. Anxiety, 2014, 31(4), 291-296.
[http://dx.doi.org/10.1002/da.22227] [PMID: 24616149]
[54]
Duman, R.S.; Li, N.; Liu, R-J.; Duric, V.; Aghajanian, G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology, 2012, 62(1), 35-41.
[http://dx.doi.org/10.1016/j.neuropharm.2011.08.044] [PMID: 21907221]
[55]
Marmol, F. Lithium: bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(8), 1761-1771.
[http://dx.doi.org/10.1016/j.pnpbp.2008.08.012] [PMID: 18789369]
[56]
Higgins, G.A.; Allyn-Feuer, A.; Barbour, E.; Athey, B.D. A glutamatergic network mediates lithium response in bipolar disorder as defined by epigenome pathway analysis. Pharmacogenomics, 2015, 16(14), 1547-1563.
[http://dx.doi.org/10.2217/pgs.15.106] [PMID: 26343379]
[57]
Gigante, A.D.; Bond, D.J.; Lafer, B.; Lam, R.W.; Young, L.T.; Yatham, L.N. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord., 2012, 14(5), 478-487.
[http://dx.doi.org/10.1111/j.1399-5618.2012.01033.x] [PMID: 22834460]
[58]
Clinton, S.M.; Meador-Woodruff, J.H. Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology, 2004, 29(7), 1353-1362.
[http://dx.doi.org/10.1038/sj.npp.1300451] [PMID: 15054476]
[59]
Wan, L-B.; Levitch, C.F.; Perez, A.M.; Brallier, J.W.; Iosifescu, D.V.; Chang, L.C.; Foulkes, A.; Mathew, S.J.; Charney, D.S.; Murrough, J.W. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J. Clin. Psychiatry, 2015, 76(3), 247-252.
[http://dx.doi.org/10.4088/JCP.13m08852] [PMID: 25271445]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 15
Year: 2020
Published on: 01 June, 2020
Page: [1398 - 1414]
Pages: 17
DOI: 10.2174/1568026620666200423094423
Price: $65

Article Metrics

PDF: 29
HTML: 4